Canavan Disease – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Canavan Disease – Pipeline Review, H2 2017’, provides an overview of the Canavan Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Canavan Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Canavan Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Canavan Disease

The report reviews pipeline therapeutics for Canavan Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Canavan Disease therapeutics and enlists all their major and minor projects

The report assesses Canavan Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Canavan Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Canavan Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Canavan Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Pfizer Inc

Turing Pharmaceuticals AG

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Canavan Disease - Overview 5

Canavan Disease - Therapeutics Development 6

Pipeline Overview 6

Pipeline by Companies 7

Pipeline by Universities/Institutes 8

Products under Development by Companies 9

Products under Development by Universities/Institutes 10

Canavan Disease - Therapeutics Assessment 11

Assessment by Target 11

Assessment by Mechanism of Action 12

Assessment by Molecule Type 14

Canavan Disease - Companies Involved in Therapeutics Development 16

Pfizer Inc 16

Turing Pharmaceuticals AG 16

Canavan Disease - Drug Profiles 17

Gene Therapy 2 to Activate Aspartoacylase for Canavan Disease - Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

Gene therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

Gene Therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

Recombinant Enzyme to Replace Aspartoacylase for Canavan Disease - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

Stem Cell Therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

TUR-007 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

Canavan Disease - Dormant Projects 23

Canavan Disease - Discontinued Products 24

Canavan Disease - Product Development Milestones 25

Featured News & Press Releases 25

Nov 09, 2017: New gene therapy developed with UNSW researchers targets brain disorders 25

Appendix 26

Methodology 26

Coverage 26

Secondary Research 26

Primary Research 26

Expert Panel Validation 26

Contact Us 26

Disclaimer 27

List of Tables

List of Tables

Number of Products under Development for Canavan Disease, H2 2017 6

Number of Products under Development by Companies, H2 2017 7

Number of Products under Development by Universities/Institutes, H2 2017 8

Products under Development by Companies, H2 2017 9

Products under Development by Universities/Institutes, H2 2017 10

Number of Products by Stage and Target, H2 2017 11

Number of Products by Stage and Mechanism of Action, H2 2017 13

Number of Products by Stage and Molecule Type, H2 2017 15

Canavan Disease – Pipeline by Pfizer Inc, H2 2017 16

Canavan Disease – Pipeline by Turing Pharmaceuticals AG, H2 2017 16

Canavan Disease – Dormant Projects, H2 2017 23

Canavan Disease – Discontinued Products, H2 2017 24

List of Figures

List of Figures

Number of Products under Development for Canavan Disease, H2 2017 6

Number of Products under Development by Companies, H2 2017 7

Number of Products by Stage and Targets, H2 2017 11

Number of Products by Mechanism of Actions, H2 2017 12

Number of Products by Stage and Mechanism of Actions, H2 2017 12

Number of Products by Molecule Types, H2 2017 14

Number of Products by Stage and Molecule Types, H2 2017 14

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports